Objective: We previously discovered a role for the extracellular domain of the transmembrane protein semaphorin 4D (Sema4D) as a fast-acting, selective, and positive regulator of functional c-aminobutyric acid (GABA)ergic synapse formation in hippocampal neuronal culture. We also demonstrated that Sema4D treatment increases inhibitory tone and suppresses hyperexcitability in an organotypic hippocampal slice culture model of epilepsy. Here, we investigate the ability of Sema4D to promote GABAergic synapse formation and suppress seizure activity in vivo in adult mice. Methods: We performed a 3-hour, intrahippocampal infusion of Sema4D or control protein into the CA1 region of adult mice. To quantify GABAergic presynaptic bouton density, we performed immunohistochemistry on hippocampal tissue sections isolated from these animals using an antibody that specifically recognizes the glutamic acid decarboxylase isoform 65 protein (GAD65), which is localized to presynaptic GABAergic boutons. To assess seizure activity, we employed 2 in vivo mouse models of epilepsy, intravenous (iv) pentylenetetrazol (PTZ) and hippocampal electrical kindling, in the presence or absence of Sema4D treatment.
| INTRODUCTION
Despite a substantial increase in the number of new antiepileptic drugs (AEDs) over the past 20 years, the prevalence of drug-resistant epilepsy remains at 20%-30% of epileptic individuals 1 ; thus, there is an urgent need for the development of novel AEDs. Historically, many epilepsy treatments have relied on enhancing inhibition. A number of first-generation AEDs such as diazepam and clonazepam increase the chloride conductance of c-aminobutyric acid (GABA) A receptors, boosting the hyperpolarizing effect of GABAergic synaptic transmission. Recent studies demonstrated seizure suppression in rodent models through local and/or temporally restricted control of neuronal inhibition using optogenetics to silence excitatory neurons or activate interneurons, designer receptors exclusively activated by designer drugs (DREADDS) to silence excitatory neurons, and transplantation of interneuron progenitor cells. [2] [3] [4] Thus, finding new ways to augment inhibitory tone in the seizing brain appears to be a viable option for new AED development. Our lab identified a novel regulator of the hippocampal inhibitory network: the transmembrane protein semaphorin 4D (Sema4D). 5 Sema4D is required for proper formation of GABAergic synapses onto hippocampal pyramidal neurons. 6, 7 In addition, bath application of a soluble human Sema4D ectodomain/mouse Fc fusion protein (Sema4D-Fc) induced a dramatic increase in GABAergic, but not glutamatergic, synapse density and synaptic activity within 2 hours of application to cultured hippocampal neurons and organotypic slice. 5 The Sema4D-Fc induced increase in synapse density requires the transmembrane protein Plexin B1, a high affinity Sema4D receptor. 5 Given these findings, we sought to determine if Sema4D application could have similar synaptogenic effects on the intact brain in adult animals and, further, if Sema4D treatment could ameliorate network hyperexcitability in rodent epilepsy models. To investigate these questions, we treated adult mice by intrahippocampal infusion of Sema4D-Fc. We observed an increase in presynaptic GABAergic bouton density at the infusion site, as well as significant suppression of seizures in 2 well-established rodent models of epilepsy. We further found a correlation between the time course of Sema4D-mediated seizure suppression and the increase in GABAergic bouton density. Together with our previous work on the prosynaptogenic effects of Sema4D in vitro, 5 our results are consistent with a model in which administration of Sema4D promotes the rapid assembly of GABAergic synapses in the hippocampus, suggesting that inhibitory synapse formation can occur quickly in the adult brain. Furthermore, Sema4D application in a discrete hippocampal region ameliorated seizure activity, supporting the hypothesis that spatially restricted modulation of the inhibitory network can limit recurrent excitation in the temporal lobe. 2, 8, 9 Our findings suggest that a novel antiepilepsy therapy could enhance network inhibition by increasing the number of GABAergic synapses through treatment with a synaptogenic molecule such as Sema4D.
| MATERIALS AND METHODS

| Animals
C57BL/6, male mice and pregnant Nile rats were purchased from the Charles River Laboratories and housed in the animal facility at Brandeis University. Animals were maintained with a 12-hour light-dark cycle. Food and water were available ad libitum. Six-week-old to 11-week-old male mice were used for in vivo studies, and P6-7 male and female rat pups were used for organotypic cultures. Animal procedures were performed with approval from the Brandeis University Institutional Animal Care and Use Committee.
removed. Stereotaxic coordinates for the hippocampus were identified according to the protocol described by Huang et al 10 A craniotomy was opened using a dental drill. A control protein in aCSF with 5% dextran-488 was infused through the intrahippocampal cannula for 3 hours at a rate of 0.2 lL per hour. After 3 hours, the cannula was removed by twisting to break the glue fix or by cutting through the infusion tubing. In the case of electrically kindled mice, infusions were performed bilaterally.
| For immunohistochemistry experiments
Mice were placed in an induction chamber with isoflurane administered at 3%-4%, and then transferred to a nose cone with isoflurane administered at 3%-4%. A small hole was drilled in the skull and a cannula was lowered to the right hippocampus. When the cannula was positioned, the isoflurane rate was adjusted to 1%-4%. We then infused the mice with 100 nmol/L Sema4D-Fc in aCSF with 5% dextran-488 or 100 nmol/L vehicle Fc control protein in aCSF with 5% dextran-488 at a rate of 100 nL per minute for 10 minutes. After infusion, the incision was sealed with dental cement, and the animal was allowed to wake from anesthesia. Three hours after the start of Sema4D infusion, mice were perfused with cold aCSF as described below.
| Intravenous PTZ model of epilepsy
After recovering from surgery for 5-10 days, mice were treated with Sema4D-Fc or vehicle for 3 hours as described earlier. After treatment, the mice were warmed for 15 minutes on a heating pad to induce blood vessel dilation. 
| Analysis of PTZ-induced seizures
Two observers were blinded to treatment condition and scored videos separately. The seizure classes used for PTZ analysis are defined in Table 1 . Prior to analysis, time thresholds from the 2 observers were combined by the following method: disagreements between observers of less than 2 seconds were resolved by random selection, and disagreements of greater than 2 seconds were resolved by discussion between the observers. Seizure threshold doses were calculated for each seizure class as d = tcr/w, where d is the PTZ dose received, t is the time since the start of infusion, c is the concentration of PTZ, r is the rate of infusion, and w is the weight of the animal. Some mice failed to display one or more specific seizure classes. In these cases, threshold dose was assigned by taking that mouse's dose at the next most severe seizure class, such that doses were reported at all classes for all mice. Some animals did not die within the 5-minute infusion period. For these animals, dose at death was imputed as the maximum dose experienced by any animal.
| Rapid hippocampal kindling model of temporal lobe epilepsy
Kindling was initiated 5-10 days after bilateral cannula and electrode implant surgeries. At the start of each stimulus session, the mice were placed in individual cages. The kindling stimulus, a 10-second duration, 20 Hz train of 1 millisecond, 0.4 mA, square pulses, was delivered 12 times per session at intervals of 30-60 minutes. 11 The mice were observed for 5 minutes from the time of delivery of each stimulus. The maximum seizure class achieved on the modified Racine scale by each mouse was recorded for each stimulus. 12 The stimulus session was repeated on 3 consecutive days. The mice were returned to their home cages between sessions. Mice were considered kindled after experiencing 4 consecutive stimulus-evoked seizures of class 3 or greater. 11 All mice achieved the kindling criterion. All mice underwent the full kindling protocol, 12 stimuli per day for 3 days, regardless of when the kindling criterion was achieved. After 3 days of kindling, the mice were returned to their home cages for a 2-day stimulus-free period. After the stimulus-free period, the mice were given a single stimulus (10-second duration, 20 Hz train of 1 milliseconds, 0.4 mA square pulses) to determine baseline evoked seizure response, as measured by changes in electroencephalography (EEG) power and behavioral seizure score. The mice were recorded for a total of 10 minutes centered on the time of stimulus delivery. Evoked responses were assessed during the 5 minutes following stimulus onset. After the baseline stimulus, mice were randomly chosen for treatment with either Sema4D-Fc or vehicle for 3 hours as described above. After treatment, the mice were given a second stimulus to determine evoked seizure response. After the second stimulus, mice were returned to their home cage for 2 days. After these 2 days, the evoked seizure response was again recorded. This time point is called "+48 hours".
We performed retrospective statistical analysis to determine whether the time course and degree of kindling differed between treatment groups during the 3-day kindling period. Repeated-measures ANOVA with Greenhouse-Geisser corrections for departure from sphericity using future treatment as a between-subjects factor, protocol day as a within-subject factor, and maximum Racine class exhibited on each day as the outcome variable, revealed a significant effect of protocol day (P < .001) but not of treatment group (P > .05) or the interaction between protocol day and treatment group (P > .05).
| EEG recording
EEG was recorded using the PAL 8200 3-channel monitoring system (Pinnacle Technologies, Lawrence, KS, USA) at a 400 Hz sampling frequency and with a 25 Hz lowpass filter. The preamplifier was connected to the bipolar electrodes and ground screw through a custom connector. EEG was recorded for 5 minutes before and 5 minutes after electrical stimulation.
| Analysis of EEG data
Power was calculated using Welch's method during the afterdischarge event (10 to 30 seconds from stimulus delivery). 13 Power was computed in the following frequency bands: delta (0.5-3 Hz), theta (3-8 Hz), alpha (8-12 Hz), and beta (12-30 Hz). The afterdischarge duration was defined as the time from the end of the stimulus presentation to the first time that the EEG signal dropped to baseline amplitude for at least 2 seconds. The effects of treatment, frequency band, and the interaction of treatment and frequency band on pretest to posttest gain in power were assessed by mixed-design ANOVA and post hoc ttests with Bonferroni corrections. One mouse was removed from the dataset prior to analysis because the recording equipment failed during the +48 hour recording session.
| Behavioral analysis of electrically kindled seizures
The scorer was blinded to treatment condition and test time (pretest, posttest, or +48 hours). Seizure behavior was scored with 1-second resolution according to a modified Racine scale (Table 2) . 12 Mean seizure scores for each animal were calculated over the first 5 minutes poststimulus, thus the reported scores are the average of 300 higher-resolution scores.
| Whole brain immunohistochemistry
Mice were anesthetized by intraperitoneal injection of ketamine/xylazine cocktail and transcardially perfused with icecold aCSF. Brains were dissected and fixed overnight in 4% formalin and then transferred to 30% sucrose for >24 hours. This fixation procedure is adapted from a protocol developed by Notter et al. 14 The brains were sectioned coronally at 40 microns on a microtome. Sections were washed 3 times for 10 minutes in 0.1% Triton/PBS. Tissue was incubated in blocking solution (0.1% Triton/PBS, 20% Slices were maintained for 7 days in vitro (DIV) at 35°C and 5% CO 2 with media replacements every 2-3 days. Slices were treated with 2 nmol/L (final concentration in the well) Sema4D-Fc (R&D Systems, 5235-S4-050) or 2 nmol/L Fc (R&D Systems, 4460MG) control protein for 2 hours. After treatment, half of the slices were fixed with 1 mL cold 4% formalin solution with 4% sucrose in PBS, followed by 1 mL cold 20% methanol/PBS. For the remaining slices, the treatment media was replaced with slice culture media. Slices were maintained for an additional 48 hours before fixation.
| Organotypic culture immunocytochemistry
Fixed slices were permeabilized overnight in 0.5% Triton X-100 in PBS placed above and beneath the cell culture inserts. After permeabilization, the slices were incubated in blocking solution (20% BSA in PBS) at room temperature for 4 hours or overnight at 4°C. The fixed slices were cut out of the culture inserts, placed on a lid of a 12-well plate, and covered with 5% bovine serum albumin (BSA)/PBS. Cutouts were blocked with [1:50] 
| Confocal imaging and image analysis
Image acquisition and quantification was performed by an experimenter blinded to condition. Analyzed images were acquired on a Nikon Eclipse Ti using a 609 objective. Representative images in Figure 1A were acquired using a 109 objective. Identical acquisition settings were maintained within experiments.
For organotypic culture experiments, z-stacks were acquired with a step size of 0.5 microns beginning at the bottom of each slice where the tissue contacted the cell culture membrane inserts. Each slice was imaged 3 times in different locations in CA1. The brightest image from each stack was used for analysis. At least 3 cells from each image were analyzed using FIJI. Neuronal somas in the CA1 principal layer were identified by NeuN staining. The perimeter of the fit ellipse to each cell was approximated
. GAD65 puncta were counted manually along the periphery of each soma. The per-cell puncta density was calculated by dividing the number of puncta by the soma perimeter.
For whole-brain sections produced after in vivo Sema4D infusion, single plane images were acquired of the infusion site and a contralateral matched position in the section. Three sections were imaged per mouse, with 3 images taken per sections in nonoverlapping regions of CA1 within the infusion site. At least 3 cells from each image were analyzed. Somas in the CA1 principal layer were identified by DAPI staining. The puncta ring around each soma was identified as the concave hull of GAD65 staining around the nucleus. The per-cell puncta density was calculated as described above. For individual puncta measurements, diameters and mean intensities were measured using the straight selection and measure tools in FIJI.
| Statistical analysis
All statistical analysis was performed using the R programming language. Specific statistical tests are described in the text and figure legends. Prior to applications of ANOVA, normality was assessed by visual inspection of box plots and by Shapiro's tests, homoscedasticity was assessed by visual inspection of box plots and by Levene's tests, and sphericity was assessed by Mauchly tests. Rank transforms were applied when normality or homoscedasticity assumptions were violated. Where appropriate, we applied Greenhouse-Geisser corrections for departure from sphericity.
| RESULTS
| Sema4D increases GABAergic bouton density in vivo
Mice received unilateral hippocampal infusions of 100 nmol/L Sema4D-Fc in artificial cerebral spinal fluid (aCSF) with 5% dextran-488. Three hours after the start of infusion, the mice were euthanized and their brains processed for immunohistochemistry ( Figure 1A ). This treatment time frame is consistent with the amount of time required for Sema4D-mediated formation of active synapses in cultured hippocampal neurons and hippocampal slice. 5 To quantify GABAergic synapse density, we performed immunostaining on coronal brain sections using an antibody that specifically recognizes the GABA synthesizing enzyme GAD65, which is concentrated at the presynaptic terminal and is regularly used in immunohistochemistry of rodent brain tissue to visualize presynaptic boutons of GABAergic synapses. [15] [16] [17] [18] [19] [20] We also treated the sections with DAPI to label cell nuclei. We imaged sections containing hippocampus proximal to the infusion site on a confocal microscope; infusion sites were identified by dextran-488 florescence ( Figure 1A ). Single plane images were taken of the ipsilateral infusion site and a matching contralateral position in the section. The nuclei of layer CA1 cells were identified by DAPI fluorescence. Presynaptic GABAergic boutons in the principal cell layer are found around neuronal somas and therefore appear as rings of punctate GAD65 immunoreactivity in proximity to DAPIstained nuclei ( Figure 1B ). GAD65 puncta density was assessed as the number of puncta in a ring divided by the perimeter of an ellipse fit to the ring. To ask if Sema4D treatment led to an increase in GABAergic bouton density, we calculated the effect of treatment within a mouse by taking the difference between the mean bouton density on the treated, ipsilateral side of the brain and the mean density on the untreated, contralateral side. We found that this difference was significantly increased in mice treated with Sema4D-Fc compared to mice treated with the vehicle solution, indicating that Sema4D treatment increases GABAergic bouton density ( Figure 1B ,C). We found no effect of Sema4D treatment on the intensity of the GAD65 immunostaining ( Figure S1A ) or the diameter of the GAD65 puncta ( Figure S1B ). These data are consistent with a recent time-lapse imaging study demonstrating that Sema4D application promotes the stabilization of GABAergic presynaptic boutons in hippocampal slice. 21 Taken together, these data suggest that Sema4D promotes the formation of new GABAergic synapses in the mouse hippocampus in vivo, most likely by stabilizing nascent presynaptic boutons.
| Sema4D treatment protects against PTZ-induced seizures
We next evaluated the hypothesis that a Sema4D-mediated increase in GABAergic synapse density would counteract the abnormal excitatory activity present during seizures. C57BL/6 male mice were implanted with cannulas targeting CA1. After recovering from surgery, the mice were treated for 3 hours by infusion of 100 nmol/L of Sema4D-Fc with 5% dextran-488 in aCSF or with vehicle 100 nmol/L Fc control protein with 5% dextran-488 in aCSF. After treatment, the mice were subjected to intravenous infusion of 1% PTZ in PBS for a maximum of 5 minutes at a rate of 0.1 mL/min (Figure 2A ). PTZ is a GABA A receptor antagonist and proconvulsant agent that induces a stereotyped, dose-dependent progression of seizure classes (Section 2, Table 1 ). [22] [23] [24] We chose the PTZ model in part because of the reproducible and quantitative nature of the timed intravenous PTZ infusion seizure paradigm as well as the paradigm's frequent use as a model for assessing anticonvulsant drug effects. 22 We found that PTZ seizure thresholds were significantly higher in mice treated with Sema4D-Fc, compared to mice treated with vehicle Fc control protein ( Figure 2B ), suggesting that Sema4D application to a discrete region of the hippocampus can suppress behavioral seizures in this model. The mean effect of Sema4D treatment on PTZ dose at myoclonic seizures (47%) is comparable to the effects of other routinely employed anticonvulsants including valproate (51%) and levetiracetam (51%; tested in CD-1 mice). 25 
| Sema4D treatment confers a temporally restricted increase in GABAergic bouton density and suppression of seizures
Next, we turned our attention to assessing the long-term effect of a 3-hour Sema4D treatment on seizure activity. Once again, we implanted mice with cannulas targeting CA1 and infused 100 nmol/L Sema4D-Fc or 100 nmol/L vehicle Fc in aCSF for 3 hours. Forty-eight hours after treatment, the mice were subjected to intravenous infusion of 1% PTZ in PBS for 5 minutes at a rate of 0.1 mL/min ( Figure 3A) . We observed no difference in PTZ seizure thresholds between Sema4D-Fc treated and Fc vehicle-treated mice 48 hours after Sema4D treatment ( Figure 3B) .
To evaluate the persistence of the Sema4D-mediated change in GABAergic bouton density, we treated mice with Sema4D-Fc or vehicle solution as described earlier (Figure 1 ). Forty-eight hours after the start of infusion, the mice were euthanized and their brains processed for immunohistochemistry; PTZ was not administered. As a positive control, a cohort of mice received the Sema4D treatment and they were euthanized 3 hours after treatment, as in Figure 1 . GAD65 immunostaining and quantification of presynaptic GABAergic bouton density were performed as above. To ask if Sema4D increased GABAergic bouton density, the effect of treatment was calculated for each mouse as the mean puncta density on the treated side of the brain minus the mean puncta density on the untreated side. We found no significant difference when comparing Sema4D-treated and vehicle-treated mice euthanized 48 hours after treatment ( Figure 3C,D) . As expected, the difference in puncta density between the ipsilateral and contralateral sides was significantly increased in mice infused with Sema4D and euthanized after 3 hours compared to mice in either 48-hour treatment group (Figure 3C,D) .
To corroborate our in vivo findings, we sought to determine the persistence of the Sema4D-mediated change in GABAergic bouton density in cultured organotypic hippocampal slices. To this end, we cultured hippocampal slices from P6-7 rat pups and treated with 2 nmol/L Sema4D-Fc or vehicle control Fc for 2 hours. After treatment, the slices were either fixed immediately or washed once with culture media to the remove Sema4D-Fc and incubated for an additional 48 hours. Immunostaining for GAD65 revealed a Sema4D-dependent increase in the density of GABAergic Sections are stained with an antibody that specifically recognizes GAD65 (red) and with DAPI (blue). Scale bar represents 10 lm. C, Density of GAD65 puncta on the perimeter of CA1 principal cell layer somas. In all cases, ipsilateral is the site of infusion and contralateral was not treated. Colored points represent individual cells and black points represent means for individual animals; black lines connecting dots indicate the same animal. Box plots summarize individual cell data. In this and all figures: in box plots, hinges represent the first and third quartiles. Statistics were performed on delta scores calculated within animal by subtracting the mean bouton density on the contralateral side from the mean bouton density on the ipsilateral side. Delta scores were significantly greater in Sema4D-treated mice than in vehicle-treated mice (P < .01, unpaired, two-tailed t-test). n = 8 mice and ≥174 cells per condition boutons juxtaposed to the cell bodies of CA1 pyramidal cells in cultures fixed immediately after treatment, compared to organotypic cultures treated with vehicle Fc protein (Figure S2A,B) . In contrast, we found no difference in GABAergic bouton density between Sema4D-Fc-and vehicle-treated cultures after a 48-hour incubation following Sema4D-Fc or vehicle withdrawal ("+48 hours" Figure S2A,B) . This result agrees with that of our previous electrophysiological study showing that 2 hours of Sema4D treatment suppresses neuronal hyperexcitability and increases inhibitory tone in organotypic hippocampal slice. 5 Furthermore, our data demonstrate a temporal correlation between the increased GABAergic bouton density as detected by immunostaining both in vitro and in vivo, and the seizure suppressing effect of Sema4D treatment.
| Sema4D treatment protects against electrically kindled seizures
To evaluate the generalizability of Sema4D-mediated seizure suppression, we turned to a second in vivo seizure model: rapid hippocampal electrical kindling. C57BL/6 male mice were implanted with bilateral cannulas targeting the dentate gyrus (DG) of the hippocampus, as well as bilateral, bipolar electrodes for stimulating and recording at the infusion sites. After a 5-to 10-day recovery period, the mice were subjected to 3 days of kindling by serial, 0.4 mA stimulation at 20 Hz, followed by a 48-hour stimulus-free rest period ( Figure 4A ).
11
After the stimulus-free period, the mice were given a single stimulus to determine baseline evoked seizure response ("pretest"), as measured by changes in EEG power and behavioral seizure score. We recorded EEG and video from each mouse for a total of 10 minutes centered on the time of stimulus delivery. Evoked responses were assessed during the 5 minutes following stimulus onset. Kindling was demonstrated by an observed increase in the magnitude of evoked behavioral seizures that was not diminished after the stimulus-free period ( Figure 4B , compare the magnitude of response between day 3 kindling stimulus and day five pretest stimulus).
Next, the mice were treated for 3 hours by bilateral infusion of 100 nmol/L Sema4D-Fc in aCSF or 100 nmol/ L vehicle Fc protein in aCSF. Treatment group assignments were random, and a retrospective analysis revealed that the time course and degree of kindling did not differ between treatment groups during the 3-day kindling period (see Section 2 for statistical analysis). Absolute values for seizure severity for each animal can be found in Figure S3 .
Although a post hoc analysis shows that pretest severity scores were higher among Sema4D-treated mice than vehicle-treated mice (P = .02906, uncorrected, unpaired, twotailed t-test; Figure S3 ), mice were randomly assigned to treatment groups without this knowledge; therefore we interpret this difference as the product of random sampling. It is important to note that the effect of kindling day did not differ between treatment groups during the 3-day kindling period.
After treatment, the mice were given a second stimulus ("posttest"), and evoked seizure response was recorded as described previously. Sema4D-Fc-treated mice exhibited a reduction in posttest behavioral seizure magnitude compared to vehicle-treated mice ( Figure 4C, "posttest") . Furthermore, compared to vehicle-treated mice, mice treated with Sema4D-Fc spent less time in kindled motor seizures (KMS), advanced seizures classified as 3 or higher on the modified Racine scale ( Figure 4D , "posttest").
11 Furthermore, the change in score from pretest to posttest cannot be explained by regression to the mean because mice tended to return to individual baselines (rather than a global mean) at the +48 hour time point ( Figure S3 ). Stimulating the DG with the seizure-evoking stimulus triggers a high amplitude EEG event called an afterdischarge ( Figure S4A) . 12 Compared to vehicle treatment, Sema4D-Fc treatment did not significantly alter the There was a significant main effect of treatment on dose, P < .01, mixed-design ANOVA on ranks.
There was no significant interaction between treatment and seizure class. n = 9 mice per condition duration of the afterdischarge ( Figure S4B ). However, Sema4D-Fc-treated mice experienced a reduction in total EEG power at the infusion site during the afterdischarge event compared to control mice ( Figure 4E ,F "posttest").
Taken together with the effect of Sema4D on PTZ-induced seizures, these results demonstrate that the antiepileptic effect of Sema4D treatment generalizes to a chronic and nonpharmacological epilepsy model. We also assayed the persistence of the effect of Sema4D treatment on seizures in the kindled mice 48 hours after Sema4D or vehicle Fc treatment. We allowed the mice a 48-hour stimulus-free period after the posttreatment test stimulus on experimental day 5 (Figure 4A) . The mice were then given a second stimulus, and evoked seizure response was measured as described previously. We observed no difference in behavioral seizure severity in Sema4D-Fc compared to vehicle-treated mice 48 hours after treatment ( Figure 4C , D "+48 hours"). In addition, the change from baseline in afterdischarge EEG power did not differ between treatment groups at the 48-hour time point ( Figure 4E ,F "+48 hours"). Together with our PTZ-induced seizure data ( Figure 3B ), these data F I G U R E 3 The antiseizure and increased GABAergic density-promoting effects of Sema4D are temporally correlated. A, Time line of the experiment shown in B. Mice (C57BL/6, male, P50-P80) were implanted unilaterally with cannulas targeting CA1, then given 5-10 days to recover. After recovery, an intrahippocampal Sema4D or vehicle treatment was administered. Forty-eight hours after treatment, PTZ was infused through the tail vein for up to 5 min. B, PTZ dose versus seizure class. There was no significant main effect of treatment on dose, and there was no significant interaction between treatment and seizure class. Mixed-design ANOVA on ranks; n = 11 vehicle-treated and n = 7 Sema4D-treated mice. (C, D) Mice (C57BL/6, male, P49-P59) were anesthetized and treated with Sema4D or vehicle solution by unilateral, intrahippocampal infusion over 10 minutes. The mice were euthanized 3 hours (n = 4 mice, all Sema4D-treated) or 48 hours (n = 6 mice, vehicle-treated and n = 5 mice, Sema4D-treated) following treatment. C, CA1 principal layer cells in coronal sections through Sema4D or vehicle-treated brains. Sections are stained with an antibody that specifically recognizes GAD65 (red) and with DAPI (blue). Scale bar represents 10 lm. D, Density of GAD65 puncta on the perimeter of CA1 principal cell layer somas. Colored points represent individual cells and black points represent means for individual animals; black lines connecting dots indicate the same animal. Box plots summarize individual-cell data. In all cases, ipsilateral is the site of infusion and contralateral was not treated. Statistics were performed by ANOVA with post hoc, Bonferroni-corrected, unpaired, two-tailed, t-tests on delta scores calculated within animal by subtracting the mean bouton density on the contralateral side from the mean bouton density on the ipsilateral side. Delta scores were significantly greater in Sema4D-treated mice euthanized 3 hours after treatment than mice of either treatment group euthanized 48 hours after treatment (P < .05). Delta scores did not differ between Sema4D and vehicle-treated mice euthanized 48 hours after treatment (P > .05) indicate that the antiseizure effects of 3 hours of Sema4D treatment are restricted to a window of less than 48 hours. The correlation between the time course of the Sema4D-mediated increase in GABAergic bouton density and antiseizure activity is consistent with the hypothesis that these 2 effects are related.
| DISCUSSION
Here we demonstrate that application of Sema4D to discrete hippocampal regions both increases the density of presynaptic GABAergic boutons and suppresses seizure activity in vivo. We also show that the effects of Sema4D on bouton density and seizures are temporally correlated. Based on these results, we propose that increased GABAergic synapse formation in response to Sema4D underlies the seizure suppressing effect of the in vivo Sema4D treatment. This model is consistent with our previous findings in cultured neurons and hippocampal slice, which demonstrated that a 2-hour Sema4D treatment is sufficient to promote functional GABAergic synapse formation. 5 Defining the precise cell biological and molecular mechanisms that underlie GABAergic synapse formation remains an active area of investigation. Time-lapse imaging studies of GABAergic synapse formation in hippocampal slice revealed that a nascent GABAergic synapse is marked by the appearance of a new, stable presynaptic GABAergic bouton that is positive for GAD65 immunoreactivity. 26 Next, postsynaptic components of GABAergic synapses, such as the scaffolding protein gephyrin, become localized in opposition to the newly formed presynaptic bouton within 2-3 hours after detection of the GABAergic bouton. 27, 28 One interesting unanswered question in our study is: what are the molecular mechanisms by which Sema4D treatment increases the density of GABAergic synaptic boutons? Our earlier studies indicate that Sema4D is localized to the synaptic membrane, signals through its conserved, extracellular Sema domain, 7 and requires the presence of the Plexin B1 receptor to promote GABAergic synapse formation. 5 In addition, Sema4D promotes GABAergic synapse formation onto both dendrites and somas of hippocampal neurons, suggesting that multiple classes of interneurons may signal through Sema4D/Plexin B1 to regulate synapse formation. 5 Time-lapse imaging studies of GAD65-GFP-labeled presynaptic boutons in organotypic hippocampal slice demonstrate that boutons are dynamic structures that appear, disappear, and reappear within a time frame of a few hours. 21, 26, 27 Of interest, Sema4D treatment promotes the stabilization of a subpopulation of these dynamic boutons, suggesting a mechanism by which Sema4D increases the density of GABAergic boutons. 21 We posit that a population of presynaptic boutons undergo similar dynamics in the adult hippocampus in vivo and that Sema4D treatment promotes the stabilization and subsequent maturation of these boutons. Furthermore, we postulate that Sema4D-dependent stabilization of presynaptic GABAergic boutons ultimately leads to increased density of functional, GABAergic synapses as GABA receptors and other components of the GABAergic postsynaptic specialization are recruited to newly stabilized boutons. A formal test of this hypothesis awaits further study. Another conclusion of our study is that administration of Sema4D unilaterally, in a discrete region of hippocampus (CA1), is effective at suppressing seizures caused by systemic administration of PTZ. This result is in line with those of other studies, which demonstrate that increased activation of inhibitory neurons in discrete hippocampal subregions is sufficient to suppress behavioral seizures in mice. 2, 8, 9, 29 For example, using the unilateral, intrahippocampal kainate mouse model of temporal lobe epilepsy (TLE), the Soltesz group demonstrated that optogenetic activation of less than 5% of parvalbumin-positive interneurons significantly reduced seizure duration, even when the activation occurred in the hippocampal region contralateral to the site of kainate injection. 2 In addition, the same group showed that cerebellar Purkinje cell activation, in either hemisphere, can also inhibit hippocampal seizures in the same TLE mouse model. 30 The success of these studies and others 31 supports the long-held belief that the hippocampus can function as a gate or "choke-point" for seizure activity in the brain. 32, 33 Our data also suggest that an antiseizure effect can be achieved by increasing GABAergic synapse density in a constrained area of the hippocampus.
In sum, our data provide strong evidence for the feasibility of a novel class of antiepileptic drugs that increase inhibitory synapse density in proepileptic brain structures. In the future, it may be fruitful to explore the potential for synergistic interactions between synaptogenic therapeutics such as Sema4D and traditional therapies. In particular, one might expect that interactions with drugs and treatment strategies that enhance GABA A R chloride currents or GABAergic neuronal activity would have multiplicative effects on total inhibitory current. For example, co-administration of Sema4D and a benzodiazepine could increase the efficacy of this first-line treatment. 34 This may be particularly relevant to epilepsies such as status epilepticus, given the discrete time window in which Sema4D appears to suppress seizure activity.
